Drug Profile

Omburtamab radiolabeled therapeutic - Memorial Sloan-Kettering Cancer Center

Alternative Names: Hu8H9 - Y-mAbs Therapeutics; HuB7-H3 radiolabeled therapeutic - Y-mAbs Therapeutics

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Memorial Sloan-Kettering Cancer Center
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2025 No recent reports of development identified for preclinical development in Solid-tumours(In adults) in USA (Parenteral)
31 Dec 2024 Y-mAbs Therapeutics terminates its license for Omburtamab radiolabeled therapeutic before December 2024
30 Mar 2023 huB7-H3 is still in preclinical trials for Solid tumours (In Adults) in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com